Beckman Coulter, Dade Behring deal

The companies cross-licensed rights to a collection of cardiac biomarkers. DADE granted BEC rights to use a combination of placental growth factor (PlGF), soluble vascular endothelial growth factor (VEGF) receptor 1 (FLT1), soluble CD40 ligand (CD154) and pregnancy-associated plasma protein A ( PAPPA, pappalysin 1). BEC granted DADE cardiac-related rights to use PAPPA. The terms of the licenses are undisclosed. ...